Murtha Cancer Center's lung cancer summit at Walter Reed focuses on research, treatment
- Category
- Military affairs
- Source
- Walter Reed National Military Medical Center
At a glance
- What
- Military Affairs
- Who
- Walter Reed National Military Medical Center
- When
- Nov 17, 2026 at 6:45 PM UTC
Statement from Walter Reed National Military Medical Center, November 17. Story by Bernard Little.
By Bernard S. Little Walter Reed National Military Medical Center Hospital Communications
For more than a decade, the John P. Murtha Cancer Center (MCC) at Walter Reed National Military Medical Center (WRNMMC) has hosted an annual lung cancer summit that brings together clinical specialists and researchers from across the Military Health System (MHS). This year’s summit held Nov. 10, 2026, again brought military healthcare providers, researchers and others to examine the latest in treatment and ongoing studies to better serve MHS beneficiaries against the disease that impacts readiness and is the most common cause of cancer deaths in the military populations.
Speakers and attendees focused on screening, diagnosis and treatment of lung cancer, which is the second most common cancer in both men and women in the United States. It follows only prostate cancer in men, and breast cancer in women, as most common in the United States, according to the American Cancer Society (ACS).
“The importance of this topic cannot be overstated,” said U.S. Navy Capt. (Dr.) Lanny Littlejohn, WRNMMC director. “Lung cancer remains the leading cause of cancer-related deaths in the United States,” he added.
The ACS estimates that in 2026 in the United States, there will be approximately 229,400 new cases of lung cancer (about 110,900 in men and 118,500 in women), and roughly 124,900 deaths from the disease (about 63,000 in men and 61,950 in women). Littlejohn said that although the five-year relative survival rate for lung cancer has risen in recent years because of advances in prevention, screening, diagnosis and treatment, “too many patients continue to be diagnosed after their disease has advanced.”
“Smoking remains the greatest preventable risk factor for lung cancer,” added Littlejohn, an emergency medicine physician. “This reinforces the continuing importance of tobacco prevention and cessation, risk assessment, and timely access to evidence-based lung-cancer screening.
In support of those prevention and cessation efforts, Walter Reed’s Great American Smokeout observance will be Nov. 19 at 11 a.m. in Bldg. 39’s food court.
MCC: DoW’s Center of Excellence for Cancer Care
When the MCC opened in 2012 at Walter Reed, it became the Department of War’s (DoW) first lung cancer screening site. It’s also DoW’s sole-designated Center of Excellence (CoE) for cancer care and research.
“[The MCC has] a strong history of lung cancer research that is ongoing in [collaboration] with the Uniformed Services University of the Health Sciences (USU), and the Joint Pathology Center (JPC), and we continue to deliver state-of-the-art treatment throughout our services, including being DoW’s first robotic-assisted bronchoscopy site,” added U.S. Army Lt. Col. (Dr.) Tara White. A pulmonologist and critical care physician at Walter Reed, White organized this year’s lung cancer summit with retired U.S. Navy Capt. (Dr.) Robert Browning, medical director for Interventional Pulmonology at Walter Reed.
In August 2023, Browning led the team at Walter Reed that performed DoW’s first robotic bronchoscopy. The advanced, minimally-invasive procedure is used to diagnose, stage, and evaluate lung cancer by allowing doctors to navigate deep into the lung's smallest, peripheral airways with high precision.
In order to provide such cutting-edge care, the MCC also partners with the Department of Veterans Affairs (VA) and National Cancer Institute (NCI) in research and care.
At this year’s summit, USU Department of Anatomy, Physiology and Genetics Associate Professor, Matthew Wilkerson, Ph.D., discussed continuing research into spatial transcriptions (tissue samples) characterization of lung adenocarcinoma (LUAD). He explained that this research has advanced an understanding of LUAD tumor biology along with providing “a very deep feature set for survival and exposure analytics.” Wilkerson also serves as director of the Data Science Division at the Center for Military Precision Health at USU.
Also, from USU, Dr. Rob Kortum, U.S. Air Force Capt. (Dr.) Jordan Valenta, and U.S. Navy Ensign Joseph LaMorta discussed ongoing research geared towards discovering lung cancer earlier and its treatment, focusing on pharmacology. They explained that this research is moving care towards greater precision therapies engineered around the molecular structure, active state and signaling biology of the mutated rat sarcoma (RAS), the most commonly mutated oncogene in human cancer.
Their research is looking to capture a deeper look into the cellular makeup of genetic variants to help discover those tumors that historically had no identifiable driving mutation, which account for approximately 50% of cancer patients. Valenta added that the research has already shown that combination therapies in lung cancer treatment, including targeting drug-tolerant persisters in RTK-mutant LUAD can effectively suppress the growth of tumors, shrink their size and delay disease progression.
Screening for Success
Because lung cancer is the most common cause of cancer deaths in the military population, it’s important to discuss strategies for system-wide optimization of screening in the MHS, according to U.S. Army Maj. (Dr.) Joshua Boster, an interventional pulmonologist and critical care physician at Walter Reed.
Although Walter Reed currently performs low-dose CT scans, Boster explained that a “structured lung cancer screening program with centralized nodule tracking and multidisciplinary care coordination” may further enhance care to MHS beneficiaries. He said this would include a systemized tracking of patients, electronic health record-based stepped reminders to inform beneficiaries about care appointments, centralized nurse navigators and program coordinators, shared decision-making, and expanding criteria for military exposures to possible cancer risks.
Lung cancer treatment
U.S. Army Majs. (Drs.) Jeffrey Lew and Cobin Helis, and U.S. Navy Lt. Cmdr. (Dr.) Lyndsey Wessels discussed lung cancer treatment including chemotherapy, immunotherapy, targeted therapy (monoclonal antibodies and inhibitors), antibody drug conjugates and tumor treating fields.
"If you are medically fit, treatment for early stage non-small cell lung cancer (NSCLC) is generally surgery," said Lew, who works in Hematology/Oncology at Walter Reed. "If you’re medically unfit, treatment is generally radiotherapy." He added that surgery and radiotherapy have roughly the same recurrence rates, with recurrence for surgery about 20% to 25% and for radiotherapy approximately 10% to 30%.
Helis, chief of Radiation Oncology at the Alexander T. Augusta Military Medical Center (ATAMMC) at Fort Belvoir, Virginia, explained that trials have shown that single-fraction stereotactic body radiation therapy (SBRT) “is a reasonable option for peripheral early NSCLC [treatment].” This therapy delivers a concentrated dose of radiation to a small tumor in a single session so that ideally surrounding (peripheral) healthy organs and tissues receive minimal or no radiation and harm.
Wessels, a cardiothoracic surgeon at Walter Reed, focused on whether surgery is still necessary if a tumor disappears. “We have not yet identified who can safely avoid surgery. The ability to sterilize a tumor does not automatically justify reducing the extent of surgery. We need prospective evidence demonstrating equivalent locoregional control and long-term survival.”
“The future may be response-adapted surgery, not simply more or less surgery,” Wessels continued. “Integration of molecular biomarkers, imaging pathologic assessment, and clinical outcomes may eventually allow us to individualize local treatment.”
Deployment-Related Respiratory Disease
U.S. Army Maj. (Dr.) Zachary Haynes and retired U.S. Navy Capt. (Dr) Joel Nations explained ongoing studies concerning deployment-related respiratory disease, including lung cancer. Nations, former chief of medicine at WRNMMC, particularly focused on the “presumptive” burn pits cause lung cancer.
Haynes, of ATAMMC’s Pulmonary and Critical Care Medicine, explained that the PACT Act of 2022 expands VA health care and disability benefits for veterans exposed to burn pits, Agent Orange, and other toxic substances during their military service.
Building on the discussion of factors that can inform lung-health care and screening, Nations added that tobacco use remains a primary modifiable risk factor for lung cancer. He added that other factors - including demographics, infections, and genetics - can also influence risk, underscoring the importance of prevention, cessation support, risk assessment, and timely screening.
“The only preventive tool we have for lung cancer is never to start smoking, and if you do smoke, consider cessation programs to help you quit,” said Nations. He added that the goal of screening is to diagnose lung cancer early when it is much more treatable, and he encouraged people to talk to their healthcare provider about being screened.
Source: Walter Reed National Military Medical Center